Clinical Trials on Moderate Varus

Total 10000 results

Beer, Kenneth R., M.D., PA
Medicis Pharmaceutical Corporation

Completed

Upper Facial Remodeling With Perlane-L and Dysport (DPL-2010)

Mild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital Rhytids

United States
University of Utah

Terminated

Moderate Sedation Educational Software

Moderate Sedation Training

United States
Evergreen General Hospital, Taiwan

Completed

Optimal Procedural Sequence in Same-day Bidirectional Endoscopy: A Prospective Randomized Controlled Study

Endoscopy | Moderate Sedation
Children's Hospital of Michigan

Completed

Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children

Moderate, Deep Sedation
University of Jena

Completed

Intervention With n3 LC-PUFA-supplemented Yogurt

Moderate Hypertriacylglycerolemic Subjects

Germany
AstraZeneca
Parexel

Recruiting

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Moderate Hepatic Impairment

United States
Sparrow Pharmaceuticals

Recruiting

Clofutriben Pharmacokinetics in Patients With Impaired Renal Function (RENAL)

Moderate Renal Impairment

United States
Meril Life Sciences Pvt. Ltd.

Not yet recruiting

Comparison of Myval THV Series With Guideline-Directed Medical Therapy in Participants With Moderate Aortic Stenosis

Moderate Aortic Stenosis

Italy, Denmark, Netherlands, Germany, Australia, Spain, Finland, Sweden, New Zealand, Switzerland, France, Brazil, Belarus, Estonia, North Macedonia, Slovakia, Slovenia, South Africa, United Kingdom, Norway
Biohm Technologies
People Science, Inc.

Active, not recruiting

Investigating the Effectiveness of 2 Different Doses of BIOHM FX Probiotic Blend in Improving Digestive Symptoms

Moderate Gastrointestinal Discomfort

United States
National Taiwan University Hospital

Unknown

GABA Antagonist to Improve Reversal of Anesthesia With High-density EEG Surveillance

Colonoscopy | Moderate Sedation

Taiwan
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Recruiting

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

Moderate to Severe Asthma

China
Sichuan Provincial People's Hospital

Recruiting

Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics (PRONEBRAINAR)

ARDS (Moderate or Severe)

China
National Taiwan University Hospital

Not yet recruiting

Combining Electrical Impedance Tomography and Thoracic Ultrasound Toinvestigate Dynamic Changes

ARDS (Moderate or Severe)
Benjamin Rose Institute on Aging
National Institute on Aging (NIA)

Recruiting

SHARE Adaptation Intervention for African-American Families (SHARE)

Mild Dementia | Moderate Dementia

United States
I.M. Sechenov First Moscow State Medical University

Completed

Sedation and Neuromediators Concentration

Deep Sedation | Moderate Sedation

Russian Federation
AbbVie

Active, not recruiting

Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece (REDEFINE)

Psoriasis | Moderate Plaque Psoriasis | Moderate Psoriasis

Greece
Nanjing RegeneCore Biotech Co., Ltd.

Not yet recruiting

Phase II Trial of RC1416 Injection in Asthma

Moderate to Severe Asthma

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

Mild to Moderate Hypertension

China
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines

Moderate-severe Glabellar Lines
Pham Ngoc Thach University of Medicine

Completed

The Effectiveness of Intervention to Increase Physical Activity and Sleep Time of Junior High School Students

Moderate Physical Activity (MPA) | Vigorous Physical Activity (VPA) | Moderate to Vigorous Physical Activity (MVPA) | Total of Sleep Time (TST)

Vietnam
Sitryx Therapeutics Ltd

Recruiting

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Bulgaria, Denmark, Germany, Ireland, United Kingdom
Akeso

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis
Dermavon Holdings Limited

Not yet recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

China
Chulalongkorn University

Recruiting

Patient Reported Outcomes and Associated Factors Following Endodontic Emergency Treatment

Moderate to Severe Endodontic Pain

Thailand
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Chongqing Claruvis Pharmaceutical Co., Ltd.

Recruiting

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Australia
Guangdong Hengrui Pharmaceutical Co., Ltd

Active, not recruiting

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

China
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AMIpharm Co., Ltd.

Completed

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Moderate or Severe Submental Fullness

Korea, Republic of
Ipsen

Completed

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

Moderate to Severe Glabellar Lines

France, Germany
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Germany, France, Belgium, Spain, United Kingdom
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States, Canada
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Moderate to Severe Glabellar Line

Korea, Republic of
Dermavon Holdings Limited

Not yet recruiting

A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

Moderate to Severe Plaque Psoriasis

China
Ipsen

Recruiting

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (LAURITE 1)

Moderate to Severe Glabellar Lines

United States, Canada
City University of Hong Kong

Not yet recruiting

Online Self-healing Program (iCBT-A)

Mild to Moderate Depressive Symptoms

China
University of KwaZulu
Heidelberg University; Technical University of Munich; Harvard School of Public... and other collaborators

Recruiting

Evaluation of Skipping Rope and Informational Pamphlet Among Adolescents in South Africa

Moderate-vigorous Physical Activity (MVPA)

South Africa
Aqpha Medical B.V.

Not yet recruiting

Safety and Performance of PTMC Dermal Filler

Moderate to Severe Nasolabial Fold
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants

Moderate to Severe Postoperative Pain

China
Daewoong Pharmaceutical Co. LTD.

Completed

DWP450 for Treating Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Galderma R&D

Completed

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AMIpharm Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat (AYP-101)

Moderate or Severe Submental Fullness

Korea, Republic of
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
EuBiologics Co.,Ltd

Completed

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

Moderate to Severe Glabellar Lines

Korea, Republic of
Allergan

Completed

Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds

Moderate to Severe Nasolabial Folds

Germany, Netherlands
Derming SRL

Completed

Efficacy and Tolerance Evaluation of an Anti-age Food Supplement

Moderate-severe Skin Aging/Photoaging
Kanuni Sultan Suleyman Training and Research Hospital

Completed

A Comparison of the Sedation During Endoscopy in Children

Failed Moderate Sedation During Procedure
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom

Clinical Trials on Moderate Varus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations